What development phase is Lorfan in?

Lorfan is FDA-approved (marketed).

What is the generic name of Lorfan?

LEVALLORPHAN is the generic (nonproprietary) name of Lorfan.

Last reviewed 2026-04-20 · How we verify

Lorfan (LEVALLORPHAN)

Roche · FDA-approved approved Small molecule Quality 10/100

Levallorphan (Lorfan), marketed by Roche, is an opioid receptor antagonist used primarily to reverse opioid overdose. Its key strength lies in its mechanism of action, which effectively binds to opioid receptors, providing a rapid response in emergency situations. The primary risk is the upcoming key patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	LEVALLORPHAN
Sponsor	Roche
Drug class	levallorphan
Target	Mu-type opioid receptor, Acetylcholinesterase, Mu-type opioid receptor
Modality	Small molecule
Therapeutic area	Rare Disease
Phase	FDA-approved
First approval	1982

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lorfan CI brief — competitive landscape report
Lorfan updates RSS · CI watch RSS
Roche portfolio CI